39 studies found for:    melanoma | Open Studies | interleukin-2
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting "Re-Stimulated" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Melanoma
Condition: Metastatic, Stage III or Stage IV, Melanoma
Interventions: Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs);   Biological: Interleukin-2
2 Recruiting Interleukin-2 in Metastatic Melanoma
Condition: Melanoma Metastatic
Intervention: Drug: Interleukin-2
3 Recruiting High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
Condition: Malignant Melanoma
Interventions: Drug: Interleukin-2;   Drug: Temozolomide
4 Recruiting HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: High Dose Interleukin-2;   Drug: Ipilimumab
5 Recruiting Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab Therapy
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Procedure: scintigraphy;   Other: laboratory biomarker analysis;   Biological: technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2
6 Recruiting A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients With Stage IV Melanoma
Condition: Malignant Melanoma
Interventions: Drug: Interleukin-2;   Drug: Ipilimumab
7 Recruiting Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: IL-2;   Drug: Interferon Alpha-2b
8 Not yet recruiting Tumor Infiltrating Lymphocytes (TIL) Transduced With TGFbDNRII
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
9 Not yet recruiting TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
Condition: Metastatic Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Genetic: Tumour Infiltrating Lymphocytes;   Drug: Interleukin-2
10 Recruiting Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: Cyclophosphamide and Interleukin 2
11 Not yet recruiting Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
Condition: Metastatic, Stage III or Stage IV, Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor-Infiltrating Lymphocytes;   Biological: Low-Dose Interleukin
12 Recruiting High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Condition: Melanoma
Interventions: Drug: HDIL-2;   Biological: recMAGE-A3 + AS15
13 Recruiting Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Condition: Metastatic Melanoma
Interventions: Other: Radiation therapy and high-dose IL-2;   Drug: High-dose IL-2
14 Recruiting T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T cells;   Biological: Interleukin-2;   Biological: Dendritic cell vaccine
15 Recruiting T-cell Based Immunotherapy for of Melanoma
Condition: Melanoma
Intervention: Biological: cyclophosphamide, fludarabine, T-cells, Interleukin-2
16 Recruiting IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Drug: Temozolomide;   Drug: Cisplatin;   Drug: Interferon Alfa-2b;   Drug: Interleukin-2
17 Recruiting Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization
Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T Cells;   Biological: Interleukin-2;   Drug: Mesna
18 Not yet recruiting Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Procedure: CD8+ T Cells;   Drug: Interleukin-2;   Drug: Ipilimumab
19 Not yet recruiting T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR)
Condition: Melanoma
Interventions: Drug: Cytoxan;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Procedure: T cell Infusion;   Drug: IL-2;   Other: Questionnaire
20 Recruiting Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Fosaprepitant

Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results
Indicates status has not been verified in more than two years